Overview

NRP104, Adderall XR or Placebo in Children Aged 6-12 Years With ADHD

Status:
Completed
Trial end date:
2004-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess, in a controlled environment, the efficacy and safety of NRP104 and Adderall XR compared to placebo in treatment of children, aged 6-12, with ADHD.
Phase:
Phase 2
Details
Lead Sponsor:
New River Pharmaceuticals
Treatments:
Adderall
Amphetamine
Lisdexamfetamine Dimesylate